Treatment of multiple sclerosis: role of natalizumab

@article{Comi2009TreatmentOM,
  title={Treatment of multiple sclerosis: role of natalizumab},
  author={Giancarlo Comi},
  journal={Neurological Sciences},
  year={2009},
  volume={30},
  pages={155-158}
}
  • G. Comi
  • Published 1 November 2009
  • Medicine
  • Neurological Sciences
The results on relapse rate and disease progression of available drugs for multiple sclerosis are shown, as well as their most relevant side effects. Results from pivotal and long-term follw-up studies support the efficacy and safety of intererons and glatiramer acetate. The treatment with mitoxantrone is limited by the occurrence of infertility, cardiotoxicy and leukaemia. Efficacy and tolerability of natalizumab are undisputable, compared to other drugs. Risks related to its treatment are PML… 
Lymphocytosis as a response biomarker of natalizumab therapeutic efficacy in multiple sclerosis
TLDR
It is suggested that NIL could be a biomarker of therapeutic efficacy in patients with RRMS treated with natalizumab, and that the risk of relapse may be higher in Patients with a lower-than-expected NIL.
Pharmacogenomics and Multiple Sclerosis: Moving Toward Individualized Medicine
TLDR
Although MS drug response biomarkers are not yet routinely implemented in the clinic, the diversity of reported, promising molecular markers is rapidly increasing and is likely to empower neurologists with an enhanced armamentarium to facilitate rational decisions on therapy and patient management.
Switch from sequestering to anti-CD20 depleting treatment: disease activity outcomes during wash-out and in the first 6 months of ocrelizumab therapy
TLDR
This study confirms that withdrawal from sequestering agents as FTY increases the risk of relapses in the wash-out period and starting OCR before achieving complete immune reconstitution could limit its effectiveness in the first 6 months probably because trapped lymphocytes escape the CD20-mediated depletion.
Available Pharmacological Options and Symptomatic Treatments of Multiple Sclerosis
TLDR
An overview of the different pharmacological therapies and their major role in the management of multiple sclerosis is provided, via exploring the most recent published scientific evidence.
iNKT Cells in Secondary Progressive Multiple Sclerosis Patients Display Pro-inflammatory Profiles
TLDR
The data suggest that the progressive phase of the disease is characterized by permanent iNKT activation and a skewing towards an inflammatory phenotype.
Effect of glatiramer acetate on disease reactivation in MS patients discontinuing natalizumab
TLDR
Patients discontinuing natalizumab are at risk of rebound of disease activity as a result of prior treatment with this drug.
A genetic variant of the anti-apoptotic protein Akt predicts natalizumab-induced lymphocytosis and post-natalizumab multiple sclerosis reactivation
TLDR
This study identified one functionally meaningful genetic variant within the Akt signaling pathway that is associated with both lymphocyte count and composition alterations during natalizumab treatment, and with the risk of disease reactivation after natalIZumab discontinuation.
A CASE OF RECURRENT DEMYELINATION
TLDR
Pediatric multiple sclerosis in children is characterized by a slightly higher preponderance in males versus females and an onset after 6 years of age and high doses of methyl prednisolone are used to treat relapses.
...
1
2
3
...

References

SHOWING 1-10 OF 49 REFERENCES
A controlled trial of natalizumab for relapsing multiple sclerosis.
TLDR
In a placebo-controlled trial, treatment with natalizumab led to fewer inflammatory brain lesions and fewer relapses over a six-month period in patients with relapsing multiple sclerosis.
Immunomodulatory agents for the treatment of relapsing multiple sclerosis: a systematic review.
TLDR
Data show that the IMAs have similar effects on several physical and inflammatory measures and Avonex has demonstrated efficacy in slowing cognitive progression in relapsing MS.
Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis
TLDR
The MRI results demonstrate that IFNB has made a significant impact on the natural history of MS in these patients and support the clinical results in showing a significant reduction in disease activity as measured by numbers of active scans and appearance of new lesions.
A study of therapy-related acute leukaemia after mitoxantrone therapy for multiple sclerosis
TLDR
The observed incidence proportion of t-AL is very low in patients who received MITO as single-agent therapy for MS, and extended follow-up of these patients and those who receive higher cumulative doses of MITO is required to define the long-term risk.
alpha4-Integrin antagonism with natalizumab: effects and adverse effects.
TLDR
It is shown that natalizumab therapy results in a reduction of CD4(+) T cells within the cerebrospinal fluid (CSF) that is ten-fold more pronounced than the reduction in the number of CD8(+) T lymphocytes, and it appears that the effect of natalIZumab on cell numbers in the CSF persists for at least 6 months after cessation of treatment.
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.
TLDR
Natalizumab reduced the risk of the sustained progression of disability and the rate of clinical relapse in patients with relapsing multiple sclerosis and hold promise as an effective treatment for relapsed multiple sclerosis.
Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.
TLDR
Natalizumab added to interferon beta-1a was significantly more effective in patients with relapsing multiple sclerosis, and additional research is needed to elucidate the benefits and risks of this combination treatment.
Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability
TLDR
The clinical benefit of glatiramer acetate for both the relapse rate and for neurologic disability was sustained at the end of the extension trial.
Selective treatment of multiple sclerosis.
  • A. Ropper
  • Medicine
    The New England journal of medicine
  • 2006
Natalizumab, a recombinant monoclonal antibody against α4 integrins, is the first selective immunomodulating drug for the treatment of multiple sclerosis and, by several criteria, is an advance over
Melanoma complicating treatment with natalizumab for multiple sclerosis.
TLDR
Two cases of melanoma in women with multiple sclerosis who were treated with natalizumab (Tysabri, Biogen Idec and Elan Pharmaceuticals), a humanized monoclonal antibody against α4 integrins are reported on.
...
1
2
3
4
5
...